KT-621 / Kymera Therap - LARVOL DELTA

KT-621, an Oral STAT6 Degrader, Improves Pruritus and Sleep in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 1b Results (EADV 2026) - P1 | "Improvements in Pruritus and Sleep With KT-621 in Adults With Moderate-to-Severe Atopic Dermatitis in the Phase 1b Trial. Outcomes by dose group and overall with once-daily dosing for 28 days starting on Day 1: (A) mean percent change from baseline in Peak Pruritus Numerical Rating Scale (PP-NRS), SCORing Atopic Dermatitis (SCORAD)-Itch, and Patient Oriented Eczema Measure (POEM)-Itch; (B) mean percent change from baseline in SCORAD-Sleeplessness and POEM-Sleep."

Clinical • P1 data • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Immunology • Insomnia • Pruritus • Sleep Disorder • Targeted Protein Degradation • IL13 • IL4 • STAT6

The spotlight is on the upcoming Phase 2b BROADEN2 trial results for KT-621, expected by year-end, which JPMorgan anticipates will meet investor expectations for efficacy (Gurufocus)

P2b data • Atopic Dermatitis

KT-621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis and comorbid asthma or allergic rhinitis: safety and evidence of clinical activity across type 2 inflammatory diseases in a phase 1b trial (ERS 2026) - "In patients with AD and comorbid asthma or allergic rhinitis, KT-621 showed improvements in FeNO and respiratory patient-reported outcomes, supporting potential efficacy across multiple Type 2 inflammatory diseases."

Clinical • P1 data • Allergic Rhinitis • Asthma • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Respiratory Diseases • IL13 • IL4 • STAT6

A Study to Evaluate Different Oral Formulations of KT-621 (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Kymera Therapeutics, Inc.

New P1 trial

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses (Investing News Network (INN)) - "...Company will present two posters featuring previously reported data from the BroADen Phase 1b trial evaluating KT-621, its first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD)....The ERS poster will highlight data from patients with AD and comorbid asthma or allergic rhinitis, while the EADV poster will focus on pruritus and sleep outcomes from the BroADen study."

P1 data • Allergic Rhinitis • Asthma • Atopic Dermatitis • Immunology

The BREADTH trial in asthma is ongoing, with topline data expected in late 2027. (Investing News Network (INN))

P1 data • Asthma • Immunology

Enrollment in the BROADEN2 trial in AD has been completed, with topline data expected by year-end 2026 and Phase 3 AD trials planned to initiate by mid-2027. (Investing News Network (INN))

Enrollment closed • New P3 trial • P1 data • Atopic Dermatitis • Immunology

KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 (The Globe and Mail)

New P3 trial • P2b data • Asthma • Atopic Dermatitis

BROADEN2: A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=200 | Active, not recruiting | Sponsor: Kymera Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

BREADTH-EXT: A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study (clinicaltrials.gov) - P2 | N=264 | Recruiting | Sponsor: Kymera Therapeutics, Inc.

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Kymera Therapeutics, Inc…completed enrollment in its BROADEN2 Phase 2b trial of KT-621 for moderate to severe atopic dermatitis nearly six months ahead of schedule (Investing.com) - "The clinical-stage biopharmaceutical company now expects to report topline data by year-end 2026, six months earlier than its previous guidance of mid-2027. Subject to regulatory discussions, Kymera plans to initiate Phase 3 trials in atopic dermatitis by mid-2027."

Enrollment closed • New P3 trial • P2b data • Atopic Dermatitis

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting (The Manila Times) - "KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively...KT-621 demonstrated rapid, deep and durable STAT6 degradation in blood and skin in healthy Japanese adults...KT-621 was generally well tolerated with no serious adverse events reported and no treatment-related adverse events leading to discontinuation...The data support the continued development of KT-621 across a broad range of Type 2 inflammatory diseases...The parallel KT-621 Phase 2b trials in atopic dermatitis and asthma are ongoing, with data expected by mid-2027 and late 2027, respectively."

P1 data • P2b data • Asthma • Atopic Dermatitis • Immunology

KT621-AS-202: A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma (clinicaltrialsregister.eu) - P1/2 | N=121 | Not yet recruiting | Sponsor: Kymera Therapeutics Inc. | N=73 ➔ 121

Enrollment change • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

KT-621 treatment induces rapid STAT6 degradation and modulation of Th2 gene transcripts in atopic dermatitis lesional skin (SID 2026) - P1 | "KT-621 demonstrated rapid, deep STAT6 degradation in blood and skin in patients with moderate-to-severe AD. Reductions in Th2, itch-related, epithelial hyperplasia, Th17/22 biomarkers and STAT6 protein expression in blood and skin over 4 weeks were associated with improvement in efficacy measures."

Late-breaking abstract • Atopic Dermatitis • Dermatitis • Dermatology • Fibrosis • Immunology • Inflammation • CCL18 • CXCL1 • IL13 • IL4 • KRT16 • OSMR • POSTN • S100A12 • STAT6

KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively (GlobeNewswire)

P1 data • P2b data • Asthma • Atopic Dermatitis • Immunology

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses (GlobeNewswire) - "New data from the Phase 1b study presented at SID further characterize STAT6 degradation by KT-621 in the skin, demonstrating robust, compartment-specific target engagement and downstream biological effects. Immunohistochemistry analyses of paired lesional skin biopsies showed that KT-621 led to marked reductions in STAT6 in both epidermal keratinocytes and the dermis after 4 weeks of treatment. Expanded transcriptomic analyses revealed significant downregulation of an AD disease-relevant gene signature, including canonical Type 2 markers, as well as genes associated with epithelial hyperplasia, itch signaling, fibrosis and tissue remodeling, and broader inflammatory pathways."

P1 data • Atopic Dermatitis

Business Highlights, Recent Developments and Upcoming Milestones (GlobeNewswire) - "...Company commenced dosing in the BREADTH Phase 2b clinical trial...Recruitment is ongoing, with data expected to be reported in late 2027...In May 2026, the Company will present on KT-621 at multiple medical meetings, including a late-breaking oral presentation at the Society of Investigative Dermatology...the Company will have a featured oral presentation at the American Thoracic Society (ATS) Annual Meeting Respiratory Innovation Summit focused on the potential of KT-621 to transform treatment paradigms in respiratory care....The Company expects to report data from the trial in the second half of 2026...Building on KT-579’s preclinical profile, the Company plans to present new data further characterizing its activity across autoimmune disease models, including IBD at Digestive Disease Week (DDW) in May, as well as lupus at the European Alliance of Associations for Rheumatology (EULAR) Congress and the Federation of Clinical Immunology Societies (FOCIS)..."

P1 data • P2b data • Preclinical • Asthma • Immunology • Inflammatory Bowel Disease • Lupus • Respiratory Diseases

KT621-AS-202: A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma (clinicaltrialsregister.eu) - P1/2 | N=73 | Not yet recruiting | Sponsor: Kymera Therapeutics Inc.

New P1/2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma (GlobeNewswire) - "KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027."

Fast track • P2b data • Asthma

KT621-AS-202: A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma (clinicaltrialsregister.eu) - P1/2 | N=9 | Not yet recruiting | Sponsor: Kymera Therapeutics Inc.

New P1/2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 (GlobeNewswire)

P2b data • Atopic Dermatitis

BROADEN2: A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Kymera Therapeutics, Inc.

Trial initiation date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Kymera Therapeutics…announced that the positive results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621…were featured in a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire) - "Data shared at AAD from the BroADen Phase 1b single-arm, open-label trial showed consistent impact across multiple pharmacodynamic and clinical measures evaluated in 22 patients with moderate-to-severe AD. After 28 days of once-daily oral dosing, KT-621 demonstrated deep STAT6 degradation across both the 100 and 200 mg dose groups tested, with median reductions of 94% in skin and 98% in blood. KT-621 also showed robust reductions in disease-relevant Type 2 inflammatory biomarkers in blood, including median TARC reduction of 74% in patients with baseline levels comparable to dupilumab studies, up to 73% reduction of Eotaxin-3, up to 56% reduction of IL-31, and up to 14% reduction of IgE."

Late-breaking abstract • P1 data • Atopic Dermatitis

Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results (AAD 2026) - No abstract available

Clinical • Late-breaking abstract • P1 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • STAT6

Parallel KT-621 Phase 2b trials in atopic dermatitis and asthma are ongoing, with data expected by mid-2027 and late-2027, respectively (GlobeNewswire)

P2b data • Asthma • Atopic Dermatitis